Navigation Links
Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:4/26/2008

NTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEGINTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEGINTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEGINTRON but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study wi
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
2. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
3. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
4. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
8. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
9. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
10. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
11. Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Today, iHealth Lab Inc. announced it ... Ltd. for its first institutional round of funding. The ... global reach, accelerate growth and innovation, and invest in ... investment, Xiaomi Ventures will join iHealth,s board of directors, ... and ecommerce. "We are very pleased to ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... Va., Sept. 20, 2011 Rock Creek Pharmaceuticals, a ... ), announced that on September 19, 2011 a utility ... Office ("PTO"). This utility patent application is based on ... various products containing anatabine and the administration of anatabine ...
... Sept. 20, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... providing health care services in China through the operations ... care hospitals and affiliated ambulatory clinics, today announced that ... to be held October 13-14, 2011 at Nomura,s Singapore ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 2Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 3Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 4
(Date:9/19/2014)... “Copay coupons,” a drug manufacturer marketing tactic ... patients with prescription drug coverage, may now be infiltrating ... from the Department of Health and Human Services ... prohibit suppliers from offering side-payments to increase sales of ... The report highlights that two recent surveys, including one ...
(Date:9/19/2014)... September 19, 2014 On September 16, ... the Platinum PR and Top Places to Work in ... York City. Camino received honorable mentions in two categories ... for its work elevating Latina voices in the media. ... and be a part of its efforts to improve ...
(Date:9/19/2014)... September 19, 2014 According to a ... the embattled blood-thinner Xarelto, named as defendants in several ... Pleas, have moved the court to dismiss those suits ... have sufficient connection with Philadelphia.* The cases include, for ... (No. 140304328; Pa. Comm. Pls., Philadelphia Cty.), which was ...
(Date:9/19/2014)... -- Although there is mounting evidence that muscle-strength ... older adults in the United States don,t engage ... research. Less than one-quarter of adults over ... Department of Health and Human Services, the study ... health and fitness and staying independent, researchers advised. ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called ... human health. This therapy has grown tremendously across USA in ... effective, safe and dependable. It has far reaching benefits for ... live a very healthy and active lifestyle even beyond their ... a senior therapist at MetroMD said, “HGH or Human Growth ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 2Health News:Xarelto Makers Seek Dismissal of Cases Brought in Philadelphia, Notes Rottenstein Law Group LLP 3Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... HealthCare announced today that it awarded 20 individuals from ... Bayer Hemophilia Awards Program (BHAP). As the largest program ... and educational initiatives around the world. Recipients were selected ... treatment and care and were honored last evening during ...
... , TULSA, Okla., July 14 ... to present a unified front representing Independent Diagnostic Testing Facilities ... medical imaging industry personnel and diagnostic clinics. The association will ... procedures that often promote early detection of cancer. , ...
... , , , , ... ) announced that it beat its original goal for first time fundraising event ... a target of $250,000. To date, it has raised more than $280,000. ... , According to Anthony Mann, founder of the bike ...
... , , ... today that its SNICKERS(R) Brand is teaming up with Feeding America to ... struggling with hunger(1). As part of ,Bar Hunger, SNICKERS ... to Feeding America in 2009. The brand will also educate and ...
... ... under the knife? Advances in fractional laser technology have resulted in the Fractional Eyelift, a ... Bruce Katz of the Juva Skin & Laser Center pioneered the procedure. , ... (PRWEB) July 14, 2009 -- For many, ...
... , VIENNA, Austria, July 14 Changes in the brain ... of risk proteins in body fluids, may lead to earlier and more ... Alzheimer,s Association 2009 International Conference on Alzheimer,s Disease (ICAD 2009) in Vienna. ... http://www.newscom.com/cgi-bin/prnh/20090529/ICADLOGO ) , ...
Cached Medicine News:Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 2Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 3Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 4Health News:Bayer HealthCare Awards $2.5 Million to Advance Hemophilia Research and Improve Patient Care 5Health News:New Medical Imaging Organization Launched to Represent Industry Personnel and Diagnostic Clinics 2Health News:JBFCS Surpasses Fundraising Goal For Hudson Valley Bike Ride Despite Difficult Financial Times 2Health News:SNICKERS(R) Brand and David Arquette Make a Big Move to Help Feeding America Bar Hunger 2Health News:SNICKERS(R) Brand and David Arquette Make a Big Move to Help Feeding America Bar Hunger 3Health News:SNICKERS(R) Brand and David Arquette Make a Big Move to Help Feeding America Bar Hunger 4Health News:Fractional Eyelift Procedure Reduces Eyelid Drooping and Wrinkles with Minimal Recovery Time 2Health News:Fractional Eyelift Procedure Reduces Eyelid Drooping and Wrinkles with Minimal Recovery Time 3Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 2Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 3Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 4Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 5Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 6Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 7Health News:Brain Imaging (MRI/PET) and Measurements of Proteins in Spinal Fluid May Improve Alzheimer's Prediction and Diagnosis 8
Provides the security of braided polyester suture and ease of an automated knot for vascular closure of 5-8Fr....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: